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Founder mutations are an important cause of Lynch syndrome and facilitate
genetic testing in specific ethnic populations. Two putative founder
mutations in MSH6 were analyzed in 2685 colorectal cancer (CRC) cases,
337 endometrial cancer (EnCa) cases and 3310 healthy controls of
Ashkenazi Jewish (AJ) descent from population-based and hospital-based
case–control studies in Israel, Canada and the United States. The carriers
were haplotyped and the age of the mutations was estimated.
MSH6 *c.3984_3987dupGTCA was found in 8/2685 CRC cases, 2/337
EnCa cases, and 1/3310 controls, consistent with a high risk of CRC (odds
ratio (OR) = 9.9, 95% confidence interval (CI) = 1.2–78.9, p = 0.0079)
and a very high risk of EnCa (OR = 19.6, 95% CI = 1.8–217.2,
p = 0.0006). MSH6 *c.3959_3962delCAAG was identified in 3/2685 CRC
cases, 2/337 EnCa cases and no controls. Each mutation was observed on
separate conserved haplotypes. MSH6 *c.3984_3987dupGTCA and
MSH6 *c.3959_3962delCAAG probably arose around 585 CE and 685 CE,
respectively. No carriers were identified in Sephardi Jews (450 cases and
490 controls). Truncating mutations MSH6 *c.3984_3987dupGTCA and
MSH6 *c.3959_3962delCAAG cause Lynch syndrome and are founder
mutations in Ashkenazi Jews. Together with other AJ founder mutations,
they contribute substantially to the incidence of CRC and EnCa and are
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Characterization of Ashkenazi Jewish founder mutations in MSH6
Lynch syndrome is the most common autosomal
dominant condition pre-disposing to colorectal
cancer (CRC). It is characterized by early onset
cancers of the colorectum, endometrium, small
bowel, ureter and renal pelvis (1), as well as other
malignancies (2). Lynch syndrome is caused by
germline mutations in mismatch-repair (MMR)
genes, the common of which occur in MLH1 (3)
and MSH2 (4), and are less frequently seen in
MSH6 (5, 6) and PMS2 (7).
The MSH6 gene is localized at chromosome
2p15–16 and consists of 10 exons encoding a 1360
amino acid protein. The MSH6 protein interacts
with the MSH2 protein to form the MutSα het-
erodimer (5). The primary function of MutSα is
to initiate the repair process by binding to DNA
mismatches detected by MSH6. The character-
istic role of this heterodimer is to correct sin-
gle mispaired bases or small insertion or deletion
loops (8). Most reports indicate an attenuated phe-
notype of MSH6 -related Lynch syndrome in com-
parison with mutations of MLH1 or MSH2 genes.
Although fewer families with MSH6 mutations
fulfill the Amsterdam criteria than families with
either MLH1 or MSH2 mutations, the characteris-
tic features of MSH6 mutation families comprise
a higher risk for CRC, endometrial, ovarian, upper
urinary tract, and stomach cancers (9). Moreover,
families with MSH6 mutations have a higher inci-
dence of extracolonic cancers in comparison with
other Lynch families (10).
Several studies have investigated the frequency
of MSH6 mutations in CRCs and endometrial
cancers (EnCas). About 10% of Lynch syndrome
CRCs and 0.3% of all CRCs are explained by
the mutations in MSH6 (11, 12). The prevalence
of MSH6 mutations in EnCa patients who were
not selected for family history is about 1.1% (13).
A recent study of 113 MSH6 families estimated
cumulative risks to age 80 years for CRC to be
44% for men and 20% for women; for EnCa, the
risk was 44%. MSH6 mutation carriers had an
8-fold increased incidence of CRC in comparison
with incidence in general population, and women
with MSH6 mutations had a 26-fold increased
incidence of EnCa (14). In families with MSH6
mutations, the onset of CRC and EnCa is signifi-
cantly delayed compared to families with MLH1
or MSH2 mutations (MSH6 vs MSH2 /MLH1 =
55 years vs 44/41 years for CRC and 55 years vs
49/48 years for EnCa) (15).
Over 500 unique variants have been identified
in MSH6 gene (16). Two recently described muta-
tions in MSH6 exon 9 are truncating mutations
identified in several families around the world:
the mutation c.3959_3962delCAAG (rs63751151)
(p.Ala1320GlufsX6) was first reported in an
EnCa patient of unknown ethnicity from the
United States, where her MSI-positive tumor
with an unmethylated MLH1 promoter was diag-
nosed at the age 71 (17) and the mutation
c.3984_3987dupGTCA (p.Leu1330ValfsX12) was
first reported to occur in an Ashkenazi Jewish (AJ)
family with a history of CRCs and adenomatous
polyps (18), and using slightly different nomencla-
ture was later reported in two families; one from
the Netherlands (9) and another family from the
United States (19). A recently published Israeli
study found c.3984_3987dupGTCA in 19 mem-
bers of four AJ families (20).
The aim of the present study was to character-
ize the MSH6 mutations c.3984_3987dupGTCA
(referred below as MSH6 *dup) and c.3959_3962
delCAAG (referred below as MSH6 *del) and esti-
mate the magnitude of the contribution of these
mutations to the Lynch syndrome in the AJ popu-
lation. The frequency of these mutations was eval-
uated in a large, population-based case–control
study in northern Israel and in series of AJ individ-
uals with colorectal, endometrial, or ovarian can-
cer, ascertained in North America. Furthermore,
we sought to establish whether these two muta-
tions are founder mutations and to calculate the
age of these mutations in the AJ population.
Materials and methods
Study samples
The present study included individuals of AJ
descent from centers in Israel, Canada, and the
United States. We studied the frequency of these
two mutations in several different types of datasets:
(i) population-based series of cases and controls
(Israel); (ii) individuals with a personal and/or fam-
ily history of CRCs and other Lynch syndrome-
associated tumors referred to high-risk clinics
(Montreal); (iii) familial gastro-intestinal can-
cer registry-based cases (Toronto); (iv) hospital-
based series of EnCa cases and controls (New
York); (v) unaffected control individuals (Montreal
and Toronto) and (vi) carriers identified through
a CLIA-certified commercial laboratory (Mayo
clinic). These datasets are described briefly below.
Population-based MECC case–control study from
Israel
DNA samples from 2685 cases and 1591 healthy
controls from the large Israeli population-based
study of CRC were genotyped at the University
of Michigan. The Molecular Epidemiology of
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Colorectal Cancer (MECC) study is a population-
based case–control study of CRC in northern
Israel. The cases include histologically confirmed
incident CRC patients between 1998 and 2009.
Population-based controls were enrolled from
the Clalit Health Services database (the largest
Israeli health care provider) and matched by year
of birth, gender, clinic, and Jewish/Non-Jewish
ethnicity.
High-risk clinics
McGill University, Montreal: Individual J2205-
2 (Table 1) was found to have the MSH6 *dup
mutation after full sequencing of MSH6. She
was diagnosed with colon and endometrial can-
cer. The family history met Bethesda guide-
lines, but did not fulfill Amsterdam criteria. Fam-
ily members of the index case were analyzed
for the mutation and haplotyped at the Jewish
General Hospital, Montreal (JGH). Additionally,
22 CRC cases and 22 unaffected individu-
als from other high-risk CRC families referred
to the cancer genetics clinic at the JGH were
analyzed for the two MSH6 mutations. All cases
were negative for other known AJ founder muta-
tions in CRC genes [MLH1 *c. 394C>G (com-
mon name D132H), MSH2 *c.1906G>C (common
name A636P), APC *c.3920T>A (common name
I1307K), BLM *c.2207_2212delATCTGAinsTAG
ATTC (common name BLM Ash)].
Familial gastro-intestinal cancer registry
A total of 490 AJ were collected through
the Familial Gastro-Intestinal Cancer Registry
(FGICR) in Toronto. DNA extracted from their
blood was tested for MSH6 exon 9 mutations. This
registry constitutes a provincial resource that regis-
ters individuals with suspected or verified heredi-
tary cancers and, for the Jewish population, also
those who underwent GI cancer screening irre-
spective of their family history of cancer. Family
histories are obtained through a standardized ques-
tionnaire.
Hospital series
A total of 337 hospital-based AJ women with
EnCa and 285 AJ female controls with a mean
age of 58 years from Memorial Sloan-Kettering
Cancer Center (MSKCC) were tested for both
MSH6 mutations.
Volunteering controls
Women’s College Hospital, Toronto: a total of
1011 AJ female controls were genotyped for
both MSH6 exon 9 mutations. The mean age of
the controls was 48.5 years, ranging from 25 to
78 years.
JGH, Montreal: a total of 423 unaffected AJ
controls (215 females, 201 males, 1 unknown)
were tested for both MSH6 mutations. The mean
age of 402 controls was 54.3 years with a range
from 18 to 93.9 years. The age was unknown for
21 controls.
Clinical laboratory series
Two carriers of MSH6*dup mutation were iden-
tified in the Mayo Medical Laboratory mutation
database. These carriers were invited to participate
in this research through the University of Michi-
gan Cancer Genetics Registry. The patients signed
written, informed consent and donated additional
blood samples for haplotype analysis.
Genotyping of MSH6 exon 9 and haplotype analysis
Methods for screening of MSH6 exon 9 for
deletions and duplications varied between different
centers, but all carriers were re-analyzed and
haplotyped at the University of Michigan. DNA
fragments containing exon 9 and microsatellite
markers were amplified using PCR. PCR product
size was determined by fragment length analysis
using ABI3730 instrument (Applied Biosystems,
Foster City, CA) and compared to the positive
control carrying MSH6 *dup and negative control
(tested by sequencing) using GeneMarker (State
College, PA) software. Samples with the fragment
size different from expected 164 base pairs were
sequenced using the same set of primers from both
sides. Single nucleotide polymorphisms (SNPs)
were analyzed by direct sequencing. Primers and




Microsatellite instability assays were performed
as described elsewhere (21) using microdissected
DNA from paraffin-embedded tissue blocks. Five
markers (BAT25, BAT26, D2S123, D5S346, and
D17S250, often called the Bethesda panel) were
PCR amplified using radioactively labeled primers.
The patterns of the microsatellite markers in nor-
mal tissue and tumor were compared to find
changes in marker length. Samples were cat-
egorized according to established criteria (7):
MSI-High (two or more markers are unstable),
MSI-Low (one marker is unstable), microsatellite
stable (MSS) ( no markers being unstable).
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Tumor samples from MSH6 exon 9 muta-
tion carriers were retrieved and tested for the
expression of MLH1, MSH2, MSH6 and PMS2
proteins. Immunohistochemistry (IHC) was per-
formed on 4-μm sections of formalin-fixed and
paraffin-embedded tissues. Sections were dried,
de-paraffinized and re-hydrated. Slides were stained
with monoclonal antibodies. The protein expres-
sion in normal lymphocytes and colonocytes adja-
cent to the tumor served as an internal positive
control.
Statistical analysis
The association between MSH6 mutations and
risk of CRC and EnCa was estimated using
Fisher’s exact test at SAS 9.1 (The SAS Insti-
tute, Cary, NC). Haplotype reconstruction was
performed using PHASE v.2.1.1 (22, 23). Uncer-
tain genotype phases in haplotype estimates were
excluded from the analysis. The age of the muta-
tion was estimated using a Bayesian MCMC link-
age disequilibrium mapping approach (DMLE+
software) (24). Genetic distance was estimated at
1 Mb corresponding to 1 cM. We assumed popula-
tion growth rate 1.125-fold per generation, consid-
ering the population of Jewish people in a north-
eastern European region of 11,000 in the year
600 and 5 million in the year 1900. Considering
a lifetime risk of CRC of 6.85%, a worldwide
population of Ashkenazi Jews of 13 million (25),
and the mutation prevalence among CRC cases
of 0.3% (duplication) and 0.1% (deletion) esti-
mated from the MECC study, we calculated the
number of disease chromosomes in AJ population:
2672 for duplication and 891 for deletion. Accord-
ingly, the proportion of mutation carrying chromo-
somes sampled was 0.00299 (8/2672) and 0.00337
(3/891) for duplication and deletion, respectively.
Results
Identification and screening for MSH6 exon 9 indel
mutations
An AJ family found to carry MSH6 *dup was eval-
uated at McGill University for Lynch syndrome.
Based on this case and prior reports of this muta-
tion in the literature, we hypothesized that this
variant might represent a founder mutation iden-
tifiable among Ashkenazi Jews. This led to a com-
prehensive search among investigators with large
series of AJ CRC cases, EnCa cases, and controls.
One further family from Montreal, one family from
Toronto, eight families from northern Israel, and
two families from MSKCC were found to carry
the same mutation. One family ascertained through
Mayo Medical Labs with MSH6 *dup mutation
was also ascertained. As the mutation screening
relied on fragment size analysis of PCR products,
a second mutation within the same region was also
recognized corresponding to a truncating mutation,
MSH6 *del in three families from northern Israel,
three families from Toronto, and two families from
MSKCC (Table 1).
Frequency of MSH6 exon 9 dup-del mutations
in Ashkenazi Jews and risk of CRC
We evaluated the frequency of MSH6 *dup and
MSH6 *del mutations in the MECC study with the
addition of control AJ individuals from multiple
centers in Israel, Canada, and the United States.
MSH6 *dup was found in 8 of 2685 (0.3%) cases
and 1 of 3310 (0.03%) controls. The only control
carrying MSH6 *dup had an EnCa at age 61
and developed cecal cancer at age 76, several
years after being ascertained as a control without
CRC. Considering this fact and epidemiologic
principles (26), we included this carrier to both
case and control groups to calculate the odds ratio
(OR). To evaluate the risk of CRC associated
with these two MSH6 mutations, we used MECC
cases (n = 2685) and controls (n = 1591) as
well as large series of healthy Ashkenazi Jews
from a study carried out at Women’s College
Research Institute, Toronto (n = 1011), MSKCC,
New York (n = 285) and JGH, Montreal (n =
423). The carriers of MSH6 had a very high risk of
CRC (OR = 9.9, 95% confidence interval (CI) =
1.2–78.6, p = 0.0079) (Table 2). The MSH6 *del
was less common, identified in 3 of 2685 (0.11%)
cases and no controls. No carriers of either
mutation were identified in 450 Sephardi Jewish
cases or 490 Sephardi Jewish controls from Israel.
MSH6*dup and MSH6*del mutations in patients
and controls from hospital-based series
At the JGH, Montreal, one of the 22 (4.5%) CRC
affected probands from high-risk CRC families
carried MSH6 *dup, and there were no MSH6 *del
mutations found.
One carrier of MSH6 *dup and three carriers of
MSH6 *del were identified in 490 AJ patients from
Toronto registry. After testing family members of
the identified carriers, two carriers of MSH6 *dup
(family 11) and four MSH6 *del carriers (families
16 and 17) were detected (Figs 1 and 2). In 337
hospital-based cases of AJ patients with EnCa from
MSKCC, two carriers (0.6%) of MSH6 *dup and
two carriers (0.6%) of MSH6 *del mutations were
516
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Table 2. Risk of colorectal and endometrial cancers among MSH6 exon 9 indel mutation carriers in an Ashkenazi Jewish population
Mutation Cases Controls OR 95%CI p-Value
CRC
c.3984_3987dupGTCA 8/2685 (0.3%) 1/3310 (0.03%) 9.9 1.2–78.9 0.0079
c.3962_3965delCAAG 3/2685 (0.1%) 0/3310 ∞ ∞ 0.0546
MSH6 exon 9 dup or del 11/2685 (0.4%) 1/3310 (0.03%) 13.6 1.8–105.1 0.0011
EnCaa
c.3984_3987dupGTCA 2/337 (0.6%) 1/3310 (0.03%) 19.6 1.8–217.2 0.0006
c.3962_3965delCAAG 2/337 (0.6%) 0/3310 ∞ ∞ <0.0001
MSH6 exon 9 dup or del 4/337 (1.2%) 1/3310 (0.03%) 39.3 4.4–352.5 <0.0001
CRC, Colorectal cancer; EnCa, endometrial cancer.
aEnCa risk was estimated from MSKCC hospital-based series.
Fig. 1. Representative families carrying c.3984_3987dupGTCA. Mutation carriers are indicated by ‘+/−’. None of the families
meet Amsterdam criteria, but history of family cancers is suggestive of mismatch-repair mutations. Probands are indicated with
arrowheads.
identified. Roughly estimated, the risk of EnCa in
AJ MSH6 *dup mutation carriers is high (OR =
19.6, 95%CI = 1.8–217.2, p = 0.0006) (Table 2).
Both affected twins from Mayo clinic were
diagnosed with sebaceous adenoma, squamous
cell carcinoma (SCC), and basal cell carcinoma
(BCC), but did not have any Lynch syndrome-
associated cancers. In one of the brothers, IHC
analysis of sebaceous adenoma showed impaired
expression of MSH6 protein. Testing for mutations
in exon 9 in MSH6 showed MSH6*dup in both
brothers.
Clinicopathological features of MSH6 founder
mutation carriers
Among all carriers the mean age at diagno-
sis of CRC was 66 years (median 67 years),
and the mean age at diagnosis of EnCa was
54 years (median 52 years). Microsatellite insta-
bility and IHC staining against mismatch-repair
(MMR) proteins were performed in carriers with
available tumor tissue (Table 1). MSI status of the
tumors was determined for 37% of carriers (10/27)
and IHC was available for three CRCs, three
517
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Fig. 2. Representative families carrying c.3959_3962delCAAG. Mutation carriers are indicated by ‘+/−’. None of the families
meet Amsterdam criteria, but the history of family cancers is suggestive of mismatch-repair mutations. RMS, Rhabdomyosarcoma.
Probands are indicated by arrowheads.
endometrial tumors, and one sebaceous adenoma.
In our data, 33% (3/10) of carriers had MSS tumors
and 67% (7/10) had MSI-High tumors. It is note-
worthy that three out of seven MSI-High tumors
were unstable in mononucleotide markers only. In
six out of seven tumors with IHC, the MSH6 pro-
tein was not expressed, while other MMR proteins
were intact (MSH2, MLH1, PMS2).
Characteristics of MSH6 mutation-positive families
A total of 19 MSH6 *dup carriers and 12 MSH6 *del
carriers from 22 unrelated families were identified
(Table 3, Figs 1 and 2). Among all carriers, 18
MSH6 *dup carriers and 8 MSH6 *del carriers were
affected with CRC or EnCa (Table 1). None of the
families met Amsterdam criteria I and only two
families met Amsterdam criteria II (families 7 and
18). Although families did not fulfill Amsterdam
criteria, the family history of cancer is suggestive
of mutations in the MMR genes. In family 11,
both mother (I.2) and daughter (II.4) had CRC,
while the daughter was diagnosed at the age of 50
followed by the diagnosis of EnCa in a year. In
families 16 and 17, the patients (I.1 and I.1) had
two synchronous colorectal tumors; the proband in
the family 7 and the patient I.2 from family 2 were
diagnosed with metachronous CRC. It is notewor-
thy that three MSH6*dup carriers had SCC and
BCC.
Haplotype analysis
To characterize the haplotypes associated with
MSH6 exon 9 deletion and duplication we ana-
lyzed four microsatellite markers (AtnACAGn,
CAn, D2S1352, D2S123) and four SNPs (rs1800
932, rs1800935, c.1146+14A>T, rs3136367) in
all identified carriers (Table 3). The markers
cover about 3.4 Mb including MSH6 sequence.
The marker AtnACAGn is approximately 144 kb
upstream of MSH6, followed by SNPs in the cod-
ing region of MSH6, two polymorphic microsatel-
lite loci (CAn, D2S1352), with the last marker
D2S123 located 32 Mb away from the 3′-UTR
of the MSH6. The physical order of the mark-
ers is tel – AtnACAGn – rs1800932 – rs1800935 –
c.1146+14A>T – rs3136367 – CAn – D2S1352 –
D2S123 – cen. Haplotype analysis showed sepa-
rate conserved haplotypes for each mutation. The
haplotype tel-163-G-C-T-G-MSH6 *dup-179-113-
225-cen was observed with MSH6 exon 9 dup
in 16/19 carriers. Three MSH6 *dup carriers had
recombination events involving the markers at
the ends of the haplotype (AtnACAGn, D2S1352,
518































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































D2S123). The MSH6 *del was associated with
the haplotype tel-151-A-T-T-G-MSH6 *del-175-
110-210-cen found in 8/12 carriers. Four MSH6
*del carriers had recombination events involving
the marker D2S1352.
Age of MSH6 exon 9 indel mutations
We estimated the age of MSH6 *dup and MSH6
*del using an established method of combined
markers that utilizes rate of recombination and
population frequency of flanking marker alle-
les (24). Using the growth rate of Ashkenazi pop-
ulation of 0.125 per generation, the estimated
age of MSH6 *dup is about 57 (45–83) gener-
ations and the age of MSH6 *del is about 53
(40–76) generations. Considering that one gen-
eration approximately equals to 25 years, the
age of the mutations are 1425 (1125–2075)
and 1325 (1000–1900) years for MSH6 *dup and
MSH6 *del, respectively. In other words, the dupli-
cation mutation probably arose around 585 CE
and the deletion mutation probably originated in
685 CE.
Discussion
In the present study, we characterized two MSH6
truncating founder mutations c.3984_3987dup
GTCA and c.3959_3962delCAAG (rs63751151)
that cause Lynch syndrome in Ashkenazi Jews.
Both MSH6 *dup and MSH6 *del create premature
stop codons and probably result in non-functional
proteins. We found 19 MSH6 *dup carriers from
14 unrelated AJ families who all share the same
haplotype associated with c.3984_3987dupGTCA,
while all 12 MSH6 *del carriers from 8 unrelated
families share a different haplotype associated with
c.3959_3962delCAAG. These results confirm that
both MSH6 *dup and MSH6 *del are founder muta-
tions in the AJ population.
The case–control settings of the MECC study
allowed us to estimate frequency and CRC related
risk of MSH6 *dup and MSH6 *del in Ashke-
nazi and Sephardi Jews. MSH6 *dup was found
in 0.3% and MSH6 *del in 0.1% of Ashkenazi
Jews with CRC, and was not observed in 940
Sephardi Jewish cases and controls. We identified
one MSH6 *dup carrier among the MECC controls,
who developed CRC after being ascertained as a
control. This carrier was included in the analy-
sis both as a control and a case. Our data indi-
cate that carriers of MSH6 *dup have an almost
10 times higher risk to develop CRC than do
non-carriers (OR = 9.9, 95% CI = 1.2–78.9, p =
0.0079). The frequency of Lynch syndrome among
unselected CRC cases is ∼3–5%, which corre-
sponds to 81–134 cases of Lynch syndrome in the
2685 MECC CRC cases. Therefore, although the
combined frequency of MSH6 *dup and MSH6 *del
mutations is only 0.4% in CRC patients of AJ
origin, the frequency of these mutations in AJ
patients with Lynch syndrome is probably 8–14%
(11 of 81–134 cases). EnCa risk, roughly esti-
mated from the hospital-based series, was about
20 times higher in the carriers of MSH6 *dup than
in non-carriers (OR = 19.6, 95% CI = 1.8–217.2,
p = 0.0006). We used the only identified AJ con-
trol carrying MSH6 *dup from the MECC study
for approximate calculation of the risk of EnCa,
although this patient had an EnCa before being
ascertained as a control. Despite the wide CIs, the
point estimates of the risk of CRC and EnCa in our
study are, however, very comparable to the risk
showed in the recent analysis of 113 families with
MSH6 mutations (14). This study found an 8-fold
increase in risk of CRC and 26-fold increase in
risk of EnCa. In addition, the fact that we only
observed one carrier in 3310 controls, and this
person later developed a Lynch-related cancer is
supportive of our conjecture that these are highly
penetrant alleles.
In our data, the mean age at diagnosis of CRC
among carriers of MSH6 exon 9 mutations was
66 years, 20 years older than in carriers of MSH2
or MLH1 mutations (44 years) (10). The mean age
at diagnosis of EnCa was 54 years, comparable
with previous studies (9). This later age of onset
may explain the fact that only two families meet
Amsterdam criteria in our data.
About half of the MSI-High tumors (3/7) were
instable in mononucleotide markers only (BAT25,
BAT26, beta-catenin) in line with previous obser-
vations that mononucleotide microsatellite markers
are more frequently affected in tumors harboring
MSH6 germline mutations (27).
Recombination events allowed estimation of
the age of the mutations. MSH6 *dup arose
∼1425 years ago in the sixth century CE, and
MSH6 *del arose ∼1325 years ago in the sev-
enth century CE, both at the time of formation
of the AJ ethnicity in Western Europe. These
mutations are much older than other previously
described Ashkenazi founder mutations in MMR
genes, such as MSH2 c.1906G>C, that probably
arose in 15th–18th century CE, but more recent
than BRCA2 c.5946delT (traditionally known as
6174delT, 3rd century BCE) and APC p.I1307K
(7th century BCE) (28). The estimated age of the
founder mutations can in part explain their fre-
quency in Ashkenazi Jews, more recent muta-
tions (MSH6 *dup, MSH6 *del) have lower than
520
Characterization of Ashkenazi Jewish founder mutations in MSH6
0.03% frequency in general population, while the
older mutations (BRCA2 c.5946delT and APC
p.I1307K) have much higher frequency of 1.5%
and 6%, respectively (29, 30).
Only a few AJ founder mutations leading to
CRC and EnCa have been described until now. In
addition to the MSH6 exon 9 deletion and dupli-
cation characterized here, previous studies report
another MMR gene mutation, MSH2 *c.1906G>C
(common name A636P), associated with increased
risk of both CRC (31) and EnCa (31, 32), as well
as mutations in APC *c.3920T>A (common name
I1307K) (30) and BLM *c.2207_2212delATCTGA
insTAGATTC (common name BLM Ash) (33) asso-
ciated with increased risk of CRC only. The
reported frequency of APC *I1307K, BLM Ash
and MSH2 *A636P among AJ CRC patients
is 12% (34), 1–3% (33), and 1% (31), respec-
tively. The frequency of MSH2 *A636P in AJ
EnCa patients is also about 1% (31). Altogether
AJ founder mutations (APC *I1307K, BLM Ash,
MSH2 *A636P, MSH6 *dup, and MSH6 *del) are
associated with approximately 14–16% of all CRC
cases and 2.2% of all EnCa cases in Ashke-
nazi Jews. The frequency of these mutations in
AJ patients with family history of CRC and/or
EnCa can be significantly higher. A panel designed
to detect known AJ founder mutations consist-
ing of APC *I1307K, BLM Ash, MSH2 *A636P,
MSH6 *dup, and MSH6 *del could have value as a
first-line screen in all AJ CRC and/or EnCa cases,
irrespective of family history, IHC or MSI status.
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10. Plaschke J, Engel C, Krüger S et al. Lower incidence of
colorectal cancer and later age of disease onset in 27
families with pathogenic MSH6 germline mutations compared
with families with MLH1 or MSH2 mutations: the German
Hereditary Nonpolyposis Colorectal Cancer Consortium. J
Clin Oncol 2004: 22 (22): 4486–4494.
11. Hampel H, Frankel WL, Martin E et al. Feasibility of screen-
ing for Lynch syndrome among patients with colorectal cancer.
J Clin Oncol 2008: 26 (35): 5783–5788.
12. Hampel H, Frankel WL, Martin E et al. Screening for the
Lynch syndrome (hereditary nonpolyposis colorectal cancer).
N Engl J Med 2005: 352 (18): 1851–1860.
13. Hampel H, Panescu J, Lockman J et al. Comment on: screen-
ing for Lynch syndrome (hereditary nonpolyposis colorectal
cancer) among endometrial cancer patients. Cancer Res 2007:
67 (19): 9603.
14. Baglietto L, Lindor NM, Dowty JG et al. Risks of Lynch
syndrome cancers for MSH6 mutation carriers. J Natl Cancer
Inst 2009: 102 (3): 193–201.
15. Wagner A, Hendriks Y, Meijers-Heijboer EJ et al. Atypical
HNPCC owing to MSH6 germline mutations: analysis of a
large Dutch pedigree. J Med Genet 2001: 38 (5): 318–322.
16. Woods MO, Williams P, Careen A et al. A new variant
database for mismatch repair genes associated with Lynch
syndrome. Hum Mutat 2007: 28 (7): 669–673.
17. Goodfellow PJ, Buttin BM, Herzog TJ et al. Prevalence of
defective DNA mismatch repair and MSH6 mutation in an
unselected series of endometrial cancers. Proc Natl Acad Sci
U S A 2003: 100 (10): 5908–5913.
18. Peterlongo P, Nafa K, Lerman GS et al. MSH6 germline
mutations are rare in colorectal cancer families. Int J Cancer
2003: 107 (4): 571–579.
19. Hegde M, Blazo M, Chong B et al. Assay validation for
identification of hereditary nonpolyposis colon cancer-causing
mutations in mismatch repair genes MLH1, MSH2, and
MSH6. J Mol Diagn 2005: 7 (4): 525–534.
20. Goldberg Y, Porat RM, Kedar I et al. An Ashkenazi founder
mutation in the MSH6 gene leading to HNPCC. Fam Cancer
2009: 9 (2): 141–150.
521
Raskin et al.
21. Boland CR, Thibodeau SN, Hamilton SR et al. A National
Cancer Institute Workshop on Microsatellite Instability for
cancer detection and familial predisposition: development of
international criteria for the determination of microsatellite
instability in colorectal cancer. Cancer Res 1998: 58 (22):
5248–5257.
22. Stephens M, Scheet P. Accounting for decay of linkage dise-
quilibrium in haplotype inference and missing-data imputation.
Am J Hum Genet 2005: 76 (3): 449–462.
23. Stephens M, Smith NJ, Donnelly P. A new statistical method
for haplotype reconstruction from population data. Am J Hum
Genet 2001: 68 (4): 978–989.
24. Reeve JP, Rannala B. DMLE+: Bayesian linkage disequilib-
rium gene mapping. Bioinformatics 2002: 18 (6): 894–895.
25. Sun S, Greenwood CM, Thiffault I et al. The HNPCC associ-
ated MSH2*1906G→C founder mutation probably originated
between 1440 CE and 1715 CE in the Ashkenazi Jewish pop-
ulation. J Med Genet 2005: 42 (10): 766–768.
26. Rothman KJ, Greenland S. Modern epidemiology, 2nd edn.
Philadelphia, PA: Lippincott-Raven, 1998.
27. Wijnen J, de Leeuw W, Vasen H et al. Familial endometrial
cancer in female carriers of MSH6 germline mutations. Nat
Genet 1999: 23 (2): 142–144.
28. Greenwood CM, Sun S, Veenstra J et al. How old is this
mutation? – A study of three Ashkenazi Jewish founder
mutations. BMC Genet 2010: 11 (1): 39.
29. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish pop-
ulation frequencies for common mutations in BRCA1 and
BRCA2. Nat Genet 1996: 14 (2): 185–187.
30. Niell BL, Long JC, Rennert G et al. Genetic anthropology
of the colorectal cancer-susceptibility allele APC I1307K:
evidence of genetic drift within the Ashkenazim. Am J Hum
Genet 2003: 73 (6): 1250–1260.
31. Foulkes WD, Thiffault I, Gruber SB et al. The founder muta-
tion MSH2*1906G→C is an important cause of hereditary
nonpolyposis colorectal cancer in the Ashkenazi Jewish pop-
ulation. Am J Hum Genet 2002: 71 (6): 1395–1412.
32. Lavie O, Gruber SB, Lejbkowicz F et al. Gynecologic malig-
nancies in Ashkenazi families with the MSH2 A636P founder
mutation. Am J Obstet Gynecol 2008: 199 (2): 148e1–148e3.
33. Gruber SB, Ellis NA, Scott KK et al. BLM heterozygosity and
the risk of colorectal cancer. Science 2002: 297 (5589): 2013.
34. Locker GY, Kaul K, Weinberg DS et al. The I1307K APC
polymorphism in Ashkenazi Jews with colorectal cancer:
clinical and pathologic features. Cancer Genet Cytogenet 2006:
169 (1): 33–38.
522
